In Utero Exposure to Carbamazepine Effects on the Fetus

  • Elisabeth Robert
  • Bengt Källén


Carbamazepine (CBZ) is an iminostilbene with a tricyclic structure. It has been in clinical use for more then twenty years and has often been considered the anticonvulsant of choice for women with seizure disorders who wish to have a pregnancy. This was based on small series of exposed women. Recently, Morrison and Rieder (1993) made a survey of the usual practice among Canadian neurologists with respect to the management of epilepsy during pregnancy. In a majority (75%) CBZ was mentioned as the drug of choice. Epidemiological studies published during the past five years indicate an increased risk for some adverse reproductive outcome, however.


Valproic Acid Trigeminal Neuralgia Spina Bifida Club Foot Total Anomalous Pulmonary Venous Connection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barry, J. E., Danks, D. M. 1974. Anticonvulsants and congenital abnormalities. Lancet. ii: 48–49. (Letter)CrossRefGoogle Scholar
  2. Battino, D., Granata, T., Binelli, S., Caccamo, M. L., Canevini, M. P., Canger, R., Croci, D., Fumarola, C., Mai, R., Molteni, F., Pardi, G., and Avanzini, G. 1992a. Intrauterine growth in the offspring of epileptic mothers. Acta NeurolScand. 86: 555–557.Google Scholar
  3. Battino, D., Binelli, S., Caccamo, M. L., Canevini, M. P., Canger, R., Como,. M. L., Croci, D., De Gianbattista, M., Granata, T. and Pardi, G. 1992b. Malformations in offspring of 315 epileptic women: a prospective study. Acta NeurolScand. 85: 204–207.Google Scholar
  4. Bell, A. D., Gerlis, L. M., Variend, S. 1986. Persistent right umbilical vein. Case report and review of literature. In. J. Cardiol. 10: 167–176.Google Scholar
  5. Bertollini, R., Källén, B., Mastroicacovo, P., and Robert, E. 1987. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur. J. Epidemiol. 3: 164–171.PubMedCrossRefGoogle Scholar
  6. Béthenod, M. and Frédérich, A. 1975. Les enfants des antiépileptiques. Pediatrie 230: 227–248.Google Scholar
  7. Bjerkedal, T., Czeizel, A., Goujard, J., Kallen, B., Mastroiacovo, P., Nevin, N., Oakley, G. Jr., and Robert, E. 1982. Valproic acid and spina bifida. Lancetii: 1096. (Letter)CrossRefGoogle Scholar
  8. Bortnichak, E. A., and Wetter, M. S. 1989. Teratogenic effects of carbamazepine. N. Engl J. Med. 321: 1480. (Letter)CrossRefGoogle Scholar
  9. Chatot, C. L., Klein, N. W., Piateh, J., and Pierro, L. J. 1980. Successful culture of rat embryos on human serum: use in the detection of teratogens. Science 207: 1471–1473.PubMedCrossRefGoogle Scholar
  10. Chatot, C. L., Klein, N. W., Clapper, M. L., Resor, S. R., Singer, W. D., Russman, B. S., Holmes, G. L., Mattson, R. H., and Cramer, J. A. 1984. Human serum teratogenicity studied by rat embryo culture: epilepsy, anticonvulsant drugs, and nutrition. Epilepsia 25: 205–216.PubMedCrossRefGoogle Scholar
  11. Crawford, P. 1993. Epilepsy and pregnancy. Seizure 2: 87–90.PubMedCrossRefGoogle Scholar
  12. Dansky, L. V. 1989. Outcome of pregnancy in pregnant epileptic women. A prospective evaluation of genetic and environmental risk factors. Ph. D. Thesis, McGill University. (Quoted from Dansky and Finnell, 1991).Google Scholar
  13. Dansky, L. V., and Finnell, R. H. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod. Toxicol. 5: 301–335.PubMedCrossRefGoogle Scholar
  14. Dow, K. E., and Riopelle, R. J. 1989. Teratogenic effects of carbamazepine. N. Engl J. Med. 321: 1480–1481. (Letter)CrossRefGoogle Scholar
  15. Dravet, C., Julian, C., Legras, C., Magaudda, A., Guerrini, R., Genton, T., Soulayrol, S., Giraud, N., Mesdjian, E., Trentin, G., Roger, J., and Aymé, S. 1992. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 42: 75–82.PubMedGoogle Scholar
  16. El-Sayed, M. G. A., Aly, A. E., Kadri, M., and Moustafa, A. M. 1983. Comparative study on the teratogenicity of some antiepileptics in the rat. East African Med. J. 60: 407–415.Google Scholar
  17. Eluma, F. O., Sucheston, M. E., Hayes, T. G, and Paulson, R. B. 1984. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-I mouse fetus. J. Craniofac. Genetics Dev. Biol 4: 191–210.Google Scholar
  18. Fedrick, J. 1973. Epilepsy and pregnancy. A report from the Oxford linkage study. Brit. Med J. ii: 442–448.CrossRefGoogle Scholar
  19. Finnell, R. H., Mohl, V. K., Bennett, G. D., and Taylor, S. M. 1986. Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratogen. Carcinogen. Mutagen. 6: 393–401.CrossRefGoogle Scholar
  20. Fritz, H., Müller, D., and Hess, R. 1976. Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. Toxicology 6: 323–330.PubMedCrossRefGoogle Scholar
  21. Froescher, W., Eichelbaum, M., Niesen, M., Altmann, D., and von Unruh, G. E. 1980. Antiepileptic therapy with carbamazepine and valproic acid during pregnancy. Acta Neurol. Scand. Suppl 79. 62: 66–67. (Abstract).Google Scholar
  22. Gladstone, DJ., Bologa, M., Maguire, C., Pastuszak, A., and Koren, G. 1992. Course of Pregnancy and Fetal Outcome Following Maternal Exposure to Carbamazepine and Phenytoin-A Prospective Study. Reprod. Toxicol. 6: 257–261.PubMedCrossRefGoogle Scholar
  23. Granström, M.-L., and Gaily, E. 1992. Psychomotor development in children of mothers with epilepsy.Neurology 42 Suppl. 5: 144–148.PubMedGoogle Scholar
  24. Granström, M.-L., and Hiilesmaa, V. K. 1982. Malformations and minor anomalies in the children of epileptic mothers: preliminary results of the prospective Helsinki study. In: Epilepsy, Pregnancy, and the Child. Ed. by Janz, D., Dam, M., Richens, A., Bossi, L, Helge, H., and Schmidt, D. Raven Press, N. Y., pp. 303–307.Google Scholar
  25. Hansson, J. W., Myrianthopoulos, M. C., Sedgwick Harvey, M. A., and Smith, D. W. 1976. Risks to the offspring of women treated with hydantoin anticonvulsants, which emphasis on the fetal hydantoin syndrome. J. Ped. 89: 662–668.CrossRefGoogle Scholar
  26. Hiilesmaa, V. K., Teramo, K., and Granström, M.-L. 1981. Fetal head growth retardation associated with maternal anti-epileptic drugs. Lancetii: 165–167.CrossRefGoogle Scholar
  27. Jain, S., and Maheshwari, M. C. 1991. A prolonged prospective follow-up study of 306 epileptic patients in New Delhi. Acta Neurol Scand. 84: 471–474.PubMedCrossRefGoogle Scholar
  28. Jones, K. L., Lacro, R. V., Johnson, K. A., and Adams, J. 1989. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl J. Med. 320: 1661–1666.PubMedCrossRefGoogle Scholar
  29. Källén, B. Maternal carbamazepine and infant spina bifida. 1994. Reprod. Toxicol. 8: in press.Google Scholar
  30. Källén, B., Robert, E., Mastroiacovo, P., MartÍnez-FrÍas, M. L., Castilla, E. E., Cocchi, G. 1989. Anticonvulsant drugs and malformations. Is there a drug specificity? Eur. J. Epidemiol. 5: 31–36.PubMedCrossRefGoogle Scholar
  31. Kaneko, S., Otani, K., Kondo, T., Fukushima, Y., Nakamura, Y., Ogawa, Y., Kan, R., Takeda, A., Nakane Y., and Teranishi, T. 1992. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 42: 68–74.PubMedCrossRefGoogle Scholar
  32. Keller, D. M. 1989. Teratogenic effects of carbamazepine. N Engl J. Med. 321: 1480. (Letter)CrossRefGoogle Scholar
  33. Koch, S., Losche, G., Jäger-Roman, E., Jakob, S., Rating, D., Deichl, A., and Helge, H. 1992. Major and minor birth malformations and antiepileptic drugs. Neurology 42 Suppl. 5: 83–88.PubMedGoogle Scholar
  34. Leavitt, A. M., Yerby, M. S., Robinson, N., Sells, C. J., and Erickson, D. M. 1992. Epilepsy in pregnancy-developmental outcome of offspring at 12 months. Neurology 42 Suppl. 5: 141–143.PubMedGoogle Scholar
  35. Lindhout, D. 1992. Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis. Neurology 42 Suppl. 5: 43–47.PubMedGoogle Scholar
  36. Lindhout, D., Meinardi, H., Meijer, J. W. A., and Nau, H. 1992a. Antiepileptic drugs and teratogenesis in two consecutive cohorts-changes in prescription policy paralleled by changes in pattern of malformations. Neurology 42 Suppl. 5: 94–110.PubMedGoogle Scholar
  37. Lindhout, D., Omtzigt, J. G. C., and Cornel, M. C. 1992b. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 42: 111–118.PubMedCrossRefGoogle Scholar
  38. Lindhout, D., Verhoef, A., and Peters, P. W. J. 1985. Teratogenicity of antiepileptic drug combinations as assessed by whole rat embryo culture. Teratology 32: 27–28A. (Abstract)Google Scholar
  39. Little, B. B., Santosramos, R, Newell, J. F, and Maberry, M. C. 1993. Megadose carbamazepine during the period of neural tube closure. Obst. Gynecol. 82: 705–708.Google Scholar
  40. Majewski, F. 1985. Teratogens of major importance: alcohol and anticonvulsants. In: The Developing Brain and Its Disorders. Ed. by Arima, M., Suzuki, Y., Yabuuchi, H. S. Karger, Basel, pp. 223–246.Google Scholar
  41. Marden, CM., Leach, M. J., and Wilson J. A. 1981. Effect of prenatal exposure to anticonvulsant agents on maternal and foetal folate concentrations in the rat. Brit. J. Pharmacol. 74: 957–958P.Google Scholar
  42. Markestad, T., Ulstein, M., and Strandjord, R. E. 1984. Outcome of pregnancy in women with epilepsy. Acta Neurol. Scand. 69 Suppl. 98: 79–80.CrossRefGoogle Scholar
  43. Morrison, G, and Rieder, M. J. 1993. Practices of epilepsy during pregnancy-a survey of Canadian neurologists. Reprod. Toxicol. 7: 55–59.PubMedCrossRefGoogle Scholar
  44. Murasaki, O., Yoshitake, K., Tachiki, H., Nakane, Y., and Kaneko, S. 1988. Reexamination of the teratological effect of antiepileptic drugs. Jap. J. Psychiat. Neurol. 42: 592–593.Google Scholar
  45. Nir, A., Weintraub, Z., Oliven, A., Kelener, J., and Lurie, M. 1990. Anatomic evidence of spontaneous intrauterine closure of a ventricular septal defect. Pediat. Cardiol. 11: 208–210.CrossRefGoogle Scholar
  46. Omtzigt, J. G. C., Los, F. J., Grobee, D. E., Pijpers, L., Jahoda, M. G. J., Brandenburg, H., Stewart, P. A., Gaillard, H. L. J., Sachs, E. S., Wladimiroff, J. W., and Lindhout, D. 1992a. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42 Suppl. 5: 119–125.PubMedGoogle Scholar
  47. Omtzigt, J. G. C., Los, F. J., Hagenaars, A. M., Stewart, P. A., Sachs, E. S., and Lindhout, D. 1992b. Prenatal diagnosis of spina-bifida-aperta after lst-trimester valproate exposure. Prenat. Diagn. 12: 893–897.PubMedCrossRefGoogle Scholar
  48. Omtzigt, J. G. C., Los, F. J., Meijer, J. W. A., and Lindhout, D. 1993. The 10, ll-epoxide-10, ll-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid-effect of dose, comedication, and relation to outcome of pregnancy. Ther. Drug. Monit. 15: 1–10.PubMedCrossRefGoogle Scholar
  49. Paulson, R. B., Paulson, G. W. and Jreissaty, S. 1979. Phenytoin and carbamazepine in the production of cleft palates in mice. Arch. Neurol. 36: 832–836.PubMedCrossRefGoogle Scholar
  50. Robertson, I. G. 1983. Cranial nerve agenesis in a fetus exposed to carbamazepine. Develop. Med. Child Neurol. 25: 540–541.PubMedCrossRefGoogle Scholar
  51. Rosa, F. W. 1983. Pregnancy outcomes with maternal carbamazepine exposure. FDA Adverse Drug Reaction Highlight-Al. Google Scholar
  52. Rosa, F. W. 1991. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324: 674–677.PubMedCrossRefGoogle Scholar
  53. Scialli, A. R., and Lione, A. 1989. Teratogenic effects of carbamazepine. N. Engl J. Med. 321: 1480. (Letter)CrossRefGoogle Scholar
  54. Scolnik, D., Nulman, I., Rovet, J., Gladstone, D., Czuchta, D., Gardner, H. A., Gladstone, R., Ashby, P., Weksberg, R., Einarson, T., Koren, G. 1994. Neurodevelopment of chidlren exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271: 767–770.PubMedCrossRefGoogle Scholar
  55. Shakir, R. A., and Abdulwahab, B. 1991. Congenital malformations before and after the onset of maternal epilepsy. Acta Neurol. Scand. 84: 153–156.PubMedCrossRefGoogle Scholar
  56. Sibley, Y. D. L., Roberts, K. D., and Silove, E. D. 1986. Surgical correction of anomalous origin of right pulmonary artery from aorta in a four day old neonate. Br. Heart J. 56: 98–100.PubMedCrossRefGoogle Scholar
  57. Silver, K., Siavalas, EX., and Andermann, E. 1992. Outcome of children born to epileptic mothers: a prospective blinded study. Neurology 42 Suppl. 3: 287. (Abstract)Google Scholar
  58. Starreveld-Zimmerman, A. A. E., Van der Kolk, W. J., Elshove, J., and Meinardi, H. 1974. Teratogenicity of antiepileptic drugs. Clin. Neurol. Neurosurg. 2: 81–95.CrossRefGoogle Scholar
  59. Strickler, S. M., Dansky, L. V., Miller, M. A., Seni, M.-H., Andermann, E., and Spielberg, S. P. 1985. Genetic predisposition to phenytoin-induced birth defects. Lancetii: 746–749.CrossRefGoogle Scholar
  60. Sullivan, F. M. and McElhatton, P. R. 1977. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol Appl Pharmacol. 40: 365–378.PubMedCrossRefGoogle Scholar
  61. Tanganelli, P., and Regesta, G. 1992. Epilepsy, pregnancy and major birth anomalies: an Italian prospective, controlled study. Neurology 42 Suppl. 5: 89–93.PubMedGoogle Scholar
  62. Van der Pol, M. C., Hadders-Algra, M., Huisjes, H. J., and Touwen, B. C. L. 1991. Antiepileptic medication in pregnancy: late effects on the children’s central nervous system development. AmJ. ObstetGynec. 164: 121–128.Google Scholar
  63. Vorhees, C. V., Acuff, K. D., Weisenburger, W. P., and Minck, D. R. 1990. Teratogenicity of carbamazepine in rats. Teratology 41: 311–317.PubMedCrossRefGoogle Scholar
  64. West, J., Burke. J. P., and Strachan, I. 1990. Carbamazepine, epilepsy and optic nerve hypoplasia. Br. J. Ophthal. 74: 511. (Letter)CrossRefGoogle Scholar
  65. Wilder, B. J. 1992. Pharmacokinetics of valproate and carbamazepine. J. Clin. Psychopharmacol. 12: 64S–68S.PubMedCrossRefGoogle Scholar
  66. Wray, S. D., Hassell, T. M., Phillips, C., and Johnston, M. C. 1982. Preliminary study of the effects of carbamazepine on congenital orofacial defects in offspring of A/J mice. Epilepsia 23: 101–110PubMedCrossRefGoogle Scholar
  67. Yerby, M. S., Leavitt, A. M., Erickson, D. M., McCormick, K. B., Loewenson, R. B., Sells, C. J., and Benedetti, T. J. 1992. Antiepileptics and the development of congenital anomalies. Neurology 42: 132–140.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Elisabeth Robert
    • 1
  • Bengt Källén
    • 2
  1. 1.Institut Européen des GénomutationsLyonFrance
  2. 2.Tornblad InstituteUniversity of LundLundSweden

Personalised recommendations